Roche (company) – Page 9

Roche, pipeline, rethink, new molecules, cancer candidates, discard pile, strategic shift, pharmaceutical industry, drug development, oncology research

Roche Streamlines Portfolio, Prioritizes High-Impact Projects After Pipeline Reduction

2 years ago talkbio0Tagged Drug Development, high-impact projects, Optimization, portfolio, Roche (company), strategic decision

Roche, pharmaceuticals, pipeline, portfolio optimization, high-impact projects, strategic decision, drug development

Roche’s Alecensa Gains FDA Approval for Postsurgical Early Lung Cancer Treatment

2 years ago talkbio0Tagged Alecensa, Approved, Malignant neoplasm of lung, Postsurgical, Roche (company), United States Food and Drug Administration

Roche, Alecensa, FDA approval, Postsurgical treatment, Early lung cancer

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

2 years ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines

Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis

2 years ago talkbio0Tagged Clinical, Lesion, Magnetic Resonance Imaging, Multiple Sclerosis, Multiple Sclerosis, Ocrevus, Relapse, Roche (company)

Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures